Skip to main content
Premium Trial:

Request an Annual Quote

NCI Grants BioMarker Strategies SBIR Funds

NEW YORK (GenomeWeb News) – BioMarker Strategies, a molecular diagnostics developer focused on tumor testing, has won a Small Business Innovation Research grant from the National Cancer Institute.

The Fast-Track SBIR grant gives the company an initial award of $254,000, a number that could increase by up to $2 million after the initial phase of the work is completed, the firm said.

The company plans to use the funds to "expedite production" of a prototype of its SnapPath live-tumor cell testing system, BioMarker Strategies CEO Karen Olson said in a statement.

Based in the Johns Hopkins Science and Technology Park in Baltimore, Md., BioMarker Strategies also is developing a series of pathway-based ex-vivo biomarker tests to guide targeted cancer therapeutics.